1. Abbas U, Glaubius R, Mubayi A, Hood G, Mellors J (2011) Predicting the Impact of ART and PrEP with overlapping regimens on HIV transmission and drug resistance in South Africa [abstract #98LB]. In: 18th conference on retroviruses and opportunistic infections, Boston, Massachusetts
2. Abdool Karim SS, Abdool Karim Q (2011) Antiretroviral prophylaxis: a defining moment in HIV control. Lancet 378:e23–e25. doi: 10.1016/S0140-6736(11)61136-7
3. Abdool Karim SS, Baxter C (2010) Chapter 16: New prevention strategies under development/investigation. In: Abdool Karim SS, Abdool Karim Q (eds) HIV/AIDS in South Africa, 2nd edn. Cambridge University Press, Cape Town, pp 268–282
4. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany ABM, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D, on behalf of the CAPRISA 004 Trial Group (2010a) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168–1174
5. Abdool Karim SS, Richardson B, Ramjee G, Hoffman I, Chirenje M, Taha T, Kapina M, Maslankowski L, Coletti A, Profy A, Moench TR, Piwowar-Manning E, Mâsse B, Hillier SL, Soto-Torres L, on behalf of the HPTN 035 Team (2010b) Safety and effectiveness of BufferGel and 0.5 % PRO2000 gel for the prevention of HIV infection in women. AIDS 25: 957–966